Laurie Sherman

Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma

Keith T. Flaherty, Caroline Robert, Peter Hersey et al. · New England Journal of Medicine · 2012 · 2.1K citations · Full text

Medicine, Oncology, Pharmacology +17

Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group

Keith T. Flaherty, Caroline Robert, Peter Hersey et al. · Zurich Open Repository and Archive (University of Zurich) · 2012 · 1.3K citations

Medicine, Oncology, Pharmacology +15

Phase II and Biomarker Study of the Dual MET/VEGFR2 Inhibitor Foretinib in Patients With Papillary Renal Cell Carcinoma

Toni K. Choueiri, Ulka N. Vaishampayan, Jonathan E. Rosenberg et al. · Journal of Clinical Oncology · 2012 · 458 citations · Full text

Medicine, Oncology, Pharmacology +17

A Phase I Study of Foretinib, a Multi-Targeted Inhibitor of c-Met and Vascular Endothelial Growth Factor Receptor 2

Joseph P. Eder, Geoffrey I. Shapiro, Leonard J. Appleman et al. · Clinical Cancer Research · 2010 · 193 citations · Full text

Medicine, Oncology, Pharmacology +17

Effect of food on the pharmacokinetics of sunitinib malate (SU11248), a multi-targeted receptor tyrosine kinase inhibitor: results from a phase I study in healthy subjects

Carlo L. Bello, Laurie Sherman, Jihao Zhou et al. · Anti-Cancer Drugs · 2006 · 134 citations

Pharmacy, Pharmacokinetics, Pharmacology +16